Corcept Therapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 12/07/2023
Corcept Therapeutics Stock Forecast and Price Target
If Corcept Therapeutics's stock price reached the average yearlong target of $36.00 given by four well-known analysts in recent months, there would be a potential upside of approximately 33.14% from its last closing price in December, 2023. This potential increase is based on a high estimate of $50.00 and a low estimate of $27.00. If you are interested in CORT stock, it is important to also consider its competitors.
33.14% Upside
Corcept Therapeutics Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, Corcept Therapeutics's Price has decreased by 20.18%, going from $19.05 to $15.21. For next year, analysts predict Fair Value of $16.08, which would mean an increase of 5.75%. Over the next eight years, experts predict that Corcept Therapeutics's Fair Value will grow at a rate of 504.60%.
Corcept Therapeutics Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Corcept Therapeutics's Revenue has grown by 31.12%, rising from $306.49M to $401.86M. For next year, analysts predict Revenue of $474.81M, which would mean an increase of 18.15%. Over the next eight years, experts predict that Corcept Therapeutics's Revenue will grow at a rate of 244.39%.
.jpg)
Corcept Therapeutics Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last three years, Corcept Therapeutics's Free Cash Flow has decreased from $135.03M to $119.91M – a 11.20% drop! In the next year, analysts believe that Free Cash Flow will reach $163.31M – an increase of 36.19%. For the next eight years, the forecast is for Free Cash Flow to grow by 32.98%.
Corcept Therapeutics Net Income Forecast for 2023 - 2025 - 2030
Corcept Therapeutics's Net Income has grown In the last three years, rising from $94.18M to $101.42M – a growth of 7.69%. In the next year, analysts believe that Net Income will reach $104.66M – an increase of 3.19%. For the next eight years, experts predict that Corcept Therapeutics's Net Income will grow at a rate of 608.34%.
Corcept Therapeutics EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Corcept Therapeutics's EBITDA has grown by 0.99%, rising from $112.31M to $113.42M. According to the 1 analysts polled, in the next year, Corcept Therapeutics's EBITDA will fall by 10.33%, reaching $101.70M. Over the next eight years, experts believe that Corcept Therapeutics's EBITDA will grow at a rate of 136.12%.
Corcept Therapeutics EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Corcept Therapeutics's EBIT has grown, moving from $111.61M to $112.63M – an increase of 0.91%. For the next year, 5 analysts project Corcept Therapeutics's EBIT to drop by 3.92%, reaching $108.22M. Looking ahead to eight years, experts forecast that EBIT will grow by 668.26%.
Corcept Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, Corcept Therapeutics's EPS has decreased by 20.18%, going from $1.09 to $0.87. For next year, analysts predict EPS of $0.92, which would mean an increase of 5.75%. Over the next eight years, experts predict that Corcept Therapeutics's EPS will grow at a rate of 504.60%.
Site Navigation
.jpg)